Introducing CHIMERNA, a collaborative project supported by ERA4HEALTH under the NANOTECMEC call. This initiative brings together academic and clinical researchers from three European countries to work toward a shared goal: developing a Hydrogel Immunomodulatory Therapy to tackle the complexities of colorectal cancer.
At its core, CHIMERNA focuses on a subcutaneously implantable hydrogel that provides controlled release of immune cell-attracting agents and precise, targeted mRNA polymeric nanomedicines. The aim? To enable immune cells within the patient to respond more effectively to cancer.
The project is led by a dedicated team of experts:
🇧🇪 Profs. Karine Breckpot & Lorenzo Franceschini (TORC-VUB)
🇪🇸 Profs. Cristina Fornaguera & Marta Guerra (IQS-URL)
🇫🇷 Prof. Guillaume Bastiat (UA)
🇪🇸 Profs. Joan Maurel & Daniel Benítez (IDIBAPS)
By combining key enabling technologies—mRNA engineering, nanoformulation, and controlled-release hydrogels—this project is moving innovative cancer therapies from the lab to clinical application.
Stay tuned as CHIMERNA takes steps toward new possibilities in cancer treatment.